

Drug Use Review (DUR) Board approves changes for Physician Administered Drugs (PAD)

The Nevada Medicaid Drug Use Review (DUR) Board met on July 18, 2024 and voted to adopt the following changes to Physician Administered Drugs (PAD) criteria, effective March 3, 2025.

Drug Class/Program	Background and Explanation of Policy Changes, Clarifications and Updates
Elaprase® (idursulfase)	<ul style="list-style-type: none">• Corrected the hierarchy within this section
Zynlonta® (loncastuximab tesirine-lpyl)	<ul style="list-style-type: none">• Removed advice to avoid exposure to direct natural or artificial sunlight• Added Universal Criteria• Updated Large B-Cell Lymphoma to B-Cell Lymphoma• Added “Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, or HHV8-positive DLBCL, not otherwise specified”• Added “Histologic Transformation of Indolent Lymphomas (follicular lymphoma or marginal zone lymphoma) to DLBCL”• Added “Monomorphic Post-Transplant Lymphoproliferative Disorders (PTLD)”• Updated the Recertification Request

Prior Authorization forms may be found on the below webpage:
<https://gatewaypa.com/> (medical pharmacy/physician administered drugs)